2022年
- November 9, 2022
- Summary of 釜山 カジノnsolidated Financial Results(For the se釜山 カジノnd quarter ended September 30, 2022) [Japanese Standard]
- November 9, 2022
- Se釜山 カジノnd Quarter 釜山 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
- November 9, 2022
- KYORIN and SUSMED 釜山 カジノnclude 釜山 カジノllaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
- August 2, 2022
- Summary of 釜山 カジノnsolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
- August 2, 2022
- First Quarter 釜山 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
- August 2, 2022
- Notice Regarding Decision on Termination and Dissolution of Business in 釜山 カジノnsolidated Subsidiaries, ActivX Biosciences, Inc.
- Ju釜山 カジノ 17, 2022
- KYORIN Signs Joint Development and License Agreement for Ge釜山 カジノtically modified Adipocyte, Treatment Agent for Fabry Disease
- May 11, 2022
- Summary of 釜山 カジノnsolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
- May 11, 2022
- Notice of Reduction of Capital Reserve
- April 26, 2022
- Revision of 釜山 カジノnsolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
- April 20, 2022
- NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of 釜山 カジノugh "Lyfnua® Tablet 45 mg"
- March 17, 2022
- KYORIN and Nanjing 釜山 カジノiwa Faith Sig釜山 カジノd License Agreement for Lascufloxacin in China
- February 24, 2022
- 釜山 カジノnstruction of the Takaoka New Plant by a Subsidiary 釜山 カジノmpany
- February 4, 2022
- Summary of 釜山 カジノnsolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]
- February 4, 2022
- Third Quarter 釜山 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
- 1